India, Nov. 9 -- Eli Lilly (LLY) reported positive Phase 3 results for Foundayo (orforglipron), showing the oral obesity medication significantly reduced the severity of obstructive sleep apnea in adults with obesity or overweight.
Obstructive sleep apnea (OSA) is a common sleep disorder in which breathing repeatedly stops and starts during sleep, increasing the risk of high blood pressure, heart disease, stroke and other health complications.
In the ATTAIN-OSA Phase 3 program, Foundayo met its primary endpoint by significantly reducing the apnea-hypopnea index (AHI), a standard measure of sleep apnea severity.
Among participants not using positive airway pressure (PAP) therapy, Foundayo reduced breathing interruption events by 21.1 per ...